ABSTRACT
Background: On March 11, 2020, the World Health Organization (WHO) proclaimed Corona-virus Infection 2019 (COVID-19) to be a pandemic. Older subjects and those with underlying medical disorders such hypertension, asthma, diabetes mellitus, chronic lung infection, cardiovascular infections, obesity, and chronic kidney infection have been shown to have a more serious infection course and a greater fatality risk. Aims and Objectives: A study on biochemical parameters of HBV positive individuals suffering from Covid 19 & its effect on their final outcome Material and Methods: The research was conducted in the Department of Biochemistry L.N. Medical College, Bhopal. 200 subjects who are Covid positive will be included in the research. Category-1-60 corona positive subjects who are Hepatitis B virus positive. Category-2-140 corona positive subjects. Results: Out of total 200 covid positive cases, 60 individuals were also HBV positive & rest were only having Covid positive status. When we compared for the pathological/ laboratory diagnostic parameters of all the covid cases, Mean White blood cell Count was more in HBV positive individuals. Lymphocyte count was grossly decreased in HBV positive individuals. Neutrophil count, Platelet count, Alanine aminotransferase, Aspartate aminotransferase, Total bilirubin, Gamma-glutamyltransferase, Alkaline phosphatase, Albumin all these were comparatively on higher side in HBV positive individuals. Conclusion: Cholangiocytes have a role in various immune response-related activities of the hepatic, and when their function is disturbed, it can cause hepatobiliary damage due to a cytopathic effect. The hypothesis that cholangiocytes express more ACE2 receptors than other cell types could help to explain why hepatic function is dysregulated.
ABSTRACT
In this article we have tried to address the plausible identification of a novel lead drug molecule against COVID-19. Nine different arsenic (As) based molecules, roxarsone derivatives were designed and optimized for computational analysis to determine its binding affinity against SARS-CoV-2. The molecules were screened based on their chemical reactivity with respect to conceptual density functional theory (CDFT) and global reactivity descriptors. The screened molecules were docked blindly against RNA dependent RNA polymerase (RdRp) using molecular docking software iGEMDOCK v2.1. On the basis of idock score in their respective catalytic domain, di-phenyl phenoxy roxarsone identified as promising inhibitor against SARS-CoV-2 with binding free energy calculated as -86.8 kcal/mol. Site specific docking was also executed with target site, receptor binding domain (RDB) of spike glycoprotein of SARS-CoV-2 whose structure was computationally designed using Phyre2 server. The interaction study of RDB with di-phenyl phenoxy roxarsone revealed a binding energy -133.3 kcal/mol. Thus it can be concluded from the above in silico experiment that screening of potential arsenic based roxarsone derivative would help in development of new therapeutic drug for COVID-19. © 2020 Scientific Publishers. All rights reserved.